Legacy Private Trust Co. Sells 1,861 Shares of Amgen Inc. $AMGN

Legacy Private Trust Co. cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 23.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,230 shares of the medical research company’s stock after selling 1,861 shares during the period. Legacy Private Trust Co.’s holdings in Amgen were worth $2,039,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after purchasing an additional 165,281 shares during the period. State Street Corp raised its stake in Amgen by 0.6% in the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after buying an additional 177,035 shares during the period. Capital International Investors raised its stake in Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after buying an additional 282,219 shares during the period. Capital World Investors lifted its position in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after buying an additional 687,735 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Wells Fargo & Company raised their price target on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday. HSBC reaffirmed a “buy” rating and set a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Finally, Rothschild & Co Redburn increased their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Stock Down 0.6%

Shares of NASDAQ AMGN opened at $347.80 on Friday. The stock has a market capitalization of $187.49 billion, a P/E ratio of 24.44, a PEG ratio of 3.45 and a beta of 0.45. The stock’s fifty day moving average is $360.29 and its 200 day moving average is $327.80. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the prior year, the company posted $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.